Anti-PDGF-CC Antibodies Convert ER-Negative Breast Cancer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for ER-negative breast cancer, particularly basal-like tumors, have limited effectiveness, with high recurrence rates and no response to anti-hormonal therapies like tamoxifen, necessitating the development of new therapeutic approaches.

Innovation Solution

The use of anti-PDGF-CC antibodies or inhibitors of PDGF-R in combination with anti-estrogen therapy to convert ER-negative breast cancers into ER-positive phenotypes, thereby making them responsive to anti-estrogen treatment, either through simultaneous or sequential administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high-dose chemotherapy is used to treat basal-like breast cancer, then treatment effectiveness is improved, but severe side effects occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidsevere side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic approach from high-dose chemotherapy to a combination of anti-PDGF-CC antibody and anti-estrogen therapy, fundamentally altering the treatment parameters to achieve effectiveness with reduced toxicity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces anti-PDGF-CC antibody as an intermediary agent that blocks the PDGF-CC signaling pathway, thereby sensitizing ER-negative breast cancer cells to anti-estrogen therapy and enabling effective treatment without chemotherapy

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If anti-estrogen therapy is used to treat ER-negative breast cancer, then treatment simplicity is maintained, but treatment effectiveness is lost

Engineering Contradiction:

Improvetreatment simplicityVSAvoidtreatment effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent changes the receptor status parameter of the cancer cells from ER-negative to ER-positive through anti-PDGF-CC treatment, thereby enabling the cancer to respond to anti-estrogen therapy that would otherwise be ineffective

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies anti-PDGF-CC antibody treatment beforehand to convert ER-negative cancer cells to an ER-positive phenotype, preparing the cancer cells to respond subsequently to anti-estrogen therapy

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20230310385A1Treatment of er-negative breast cancer with an PDGF-CC inhibitor and an Anti-estrogen

Publication Date: 2023.10.05 PARACRINE THERAPEUTICS AB

AI summary

Disclosed is that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype, by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the present disclosure finds that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.